Days
At A Glance
Speakers
Session Type
Search
Sat 18 May 2019
Sat 18
Sun 19 May 2019
Sun 19
Mon 20 May 2019
Mon 20
Tue 21 May 2019
Tue 21
All
Type
No focus area
Workshop
Oral
Expert
Plenary
Catering and Social
Nurse
Other
Symposium
Not specified
Hide all
Show all
Saturday 18 May
1 sessions
07:30 - 08:45
Registration
tbc
Sunday 19 May
6 sessions
07:30 - 08:45
Registration
tbc
13:45 - 14:45
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Ipsen
Forum 2
Chair: Maria Fleseriu (USA)
SAT1.1
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Chairperson’s welcome and introduction
Maria Fleseriu
Oregon, USA
SAT1.2
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Patient-Reported Challenges: Are We Prepared to Listen? (focus acromegaly)
Susan Webb
SAT1.3
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
The Impact of Illness: The Perception Gap Between Us (focus Carcinoid Syndrome)
Simona Glasberg
SAT1.4
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
The real impact of endocrine disease: Understanding the patient perspective
Daphne Adelman
SAT1.5
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Moving Forward Together
Maria Fleseriu
Oregon, USA
13:45 - 14:45
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Merck KGaA
Salle Gratte-Ciel 1+2+3
Chair: George J Kahaly (Germany)
SAT3.1
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Prediabetes: A call for Action
Ian Campbell
SAT3.2
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Drug induced thyroiditis: targeting profile patient
Frederic Castinetti
13:45 - 14:45
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Takeda
Forum 1
Chair: Pascal Houillier (France)
SAT2.1
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Welcome and introduction
Pascal Houillier
SAT2.2
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Chronic hypoPT and its impact on symptoms, comorbidities and QoL
Lars Rejnmark
SAT2.3
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Renal complications in the patient with hypoPT
Pascal Houillier
SAT2.4
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Genetic syndromes as a cause of hypoPT: What are the unique challenges?
Maria Luisa Brandi
Florence, Italy
SAT2.5
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Panel discussion and Q&A
SAT2.6
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Summary and close
Pascal Houillier
17:45 - 19:15
Lipodystrophy: a shared journey for patients and care teams
Aegerion
Salle Gratte-Ciel 1+2+3
Chair: Ferrucio Santini (Italy)
SAT4.1
Lipodystrophy: a shared journey for patients and care teams
Introduction
Ferrucio Santini
SAT4.2
Lipodystrophy: a shared journey for patients and care teams
Planning the journey: suspecting and diagnosing lipodystrophy – the role of leptin deficiency in the disease
Giovani Ceccarini
SAT4.3
Lipodystrophy: a shared journey for patients and care teams
Making the journey: what are our options for treating lipodystrophy?
Michael Stumvoll
SAT4.4
Lipodystrophy: a shared journey for patients and care teams
The travel journal: patient experiences and collective learnings
Ferrucio Santini
SAT4.5
Lipodystrophy: a shared journey for patients and care teams
Discussion
All
17:45 - 19:15
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
HRA Pharma Rare Diseases
Forum 2
Chairs: Antoine Tabarin (France) & Elena Valassi (Spain)
SAT5.1
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
How to preserve bone health?
Iacopo Chiodini
SAT5.2
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Is there a clear path to progress in thrombosis risk reduction?
Richard Feelders
SAT5.3
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Should neurocognitive functioning be front of mind in management strategies?
Cornelia Andela
Monday 20 May
5 sessions
07:30 - 08:45
Registration
tbc
13:45 - 14:45
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Pfizer
Forum 2
Chair: Thierry Brue (France)
SAT6.1
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Welcome and Introduction
Thierry Brue
SAT6.2
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
A brief history of ACROSTUDY™
Michael Buchfelder
Erlangen, Germany
SAT6.3
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Key outcomes: exploring safety and treatment outcomes
Nicholas Tritos
SAT6.4
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Impact of treatment on glucose metabolism and patient-reported outcomes
Silvia Grottoli
SAT6.5
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Summary and Q&A
Thierry Brue
13:45 - 14:45
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Novo Nordisk
Lumiere Auditorium
Chair: Philippe Chanson (France)
SAT7.1
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Rationale for GH therapy in Adults with GH deficiency
Christian Strasburger
SAT7.2
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Updates in the diagnosis and management of Adults GH Deficiency
Beverly Biller
SAT7.3
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Future developments in the management of AGHD
Gudmundur Johannsson
13:45 - 14:45
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Takeda
Forum 3
Chair: Peter Kamenicky (France)
SAT8.1
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
New perspectives for not adequately controlled hypoPT
Peter Kamenicky
SAT8.2
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Working towards a consensus to define patients with not adequately controlled hypoPT
Peter Kamenicky
SAT8.3
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Treating not adequately controlled hypoPT patients with complications and comorbidities
John Bilezikian
SAT8.4
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Management of not adequately controlled hypoPT patients with impaired biochemical control and complications
Lorenz Hofbauer
SAT8.5
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Panel discussion and Q&A
SAT8.6
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Summary and close
Peter Kamenicky
18:00 - 19:30
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Advanced Accelerator Applications
Salle Gratte-Ciel 1+2+3
Chairs: Eric Baudin (France) & Woutter de Herder (Netherlands) & Diego Ferone (Italy)
SAT9.1
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Should theragnostics be reserved to a subset of patients?
Eric Baudin
SAT9.2
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Theragnostics as a new paradigm for all NET patients
Woutter Herder
SAT9.3
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
What should we do in our practice?
Diego Ferone
Tuesday 21 May
1 sessions
07:30 - 08:45
Registration
tbc
All
Sun 19
SAT4.5
Lipodystrophy: a shared journey for patients and care teams
Discussion
All
Daphne Adelman
Sun 19
SAT1.4
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
The real impact of endocrine disease: Understanding the patient perspective
Daphne Adelman
Cornelia Andela
Sun 19
SAT5.3
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Should neurocognitive functioning be front of mind in management strategies?
Cornelia Andela
Eric Baudin
Mon 20
SAT9.1
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Should theragnostics be reserved to a subset of patients?
Eric Baudin
John Bilezikian
Mon 20
SAT8.3
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Treating not adequately controlled hypoPT patients with complications and comorbidities
John Bilezikian
Beverly Biller
Mon 20
SAT7.2
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Updates in the diagnosis and management of Adults GH Deficiency
Beverly Biller
Maria Luisa Brandi
Florence, Italy
Sun 19
SAT2.4
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Genetic syndromes as a cause of hypoPT: What are the unique challenges?
Maria Luisa Brandi
Florence, Italy
Thierry Brue
Mon 20
SAT6.1
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Welcome and Introduction
Thierry Brue
Mon 20
SAT6.5
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Summary and Q&A
Thierry Brue
Michael Buchfelder
Erlangen, Germany
Mon 20
SAT6.2
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
A brief history of ACROSTUDY™
Michael Buchfelder
Erlangen, Germany
Ian Campbell
Sun 19
SAT3.1
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Prediabetes: A call for Action
Ian Campbell
Frederic Castinetti
Sun 19
SAT3.2
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Drug induced thyroiditis: targeting profile patient
Frederic Castinetti
Giovani Ceccarini
Sun 19
SAT4.2
Lipodystrophy: a shared journey for patients and care teams
Planning the journey: suspecting and diagnosing lipodystrophy – the role of leptin deficiency in the disease
Giovani Ceccarini
Iacopo Chiodini
Sun 19
SAT5.1
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
How to preserve bone health?
Iacopo Chiodini
Richard Feelders
Sun 19
SAT5.2
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Is there a clear path to progress in thrombosis risk reduction?
Richard Feelders
Diego Ferone
Mon 20
SAT9.3
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
What should we do in our practice?
Diego Ferone
Maria Fleseriu
Oregon, USA
Sun 19
SAT1.1
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Chairperson’s welcome and introduction
Maria Fleseriu
Oregon, USA
Sun 19
SAT1.5
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Moving Forward Together
Maria Fleseriu
Oregon, USA
Simona Glasberg
Sun 19
SAT1.3
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
The Impact of Illness: The Perception Gap Between Us (focus Carcinoid Syndrome)
Simona Glasberg
Silvia Grottoli
Mon 20
SAT6.4
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Impact of treatment on glucose metabolism and patient-reported outcomes
Silvia Grottoli
Woutter Herder
Mon 20
SAT9.2
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Theragnostics as a new paradigm for all NET patients
Woutter Herder
Lorenz Hofbauer
Mon 20
SAT8.4
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Management of not adequately controlled hypoPT patients with impaired biochemical control and complications
Lorenz Hofbauer
Pascal Houillier
Sun 19
SAT2.1
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Welcome and introduction
Pascal Houillier
Sun 19
SAT2.3
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Renal complications in the patient with hypoPT
Pascal Houillier
Sun 19
SAT2.6
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Summary and close
Pascal Houillier
Gudmundur Johannsson
Mon 20
SAT7.3
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Future developments in the management of AGHD
Gudmundur Johannsson
Peter Kamenicky
Mon 20
SAT8.1
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
New perspectives for not adequately controlled hypoPT
Peter Kamenicky
Mon 20
SAT8.2
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Working towards a consensus to define patients with not adequately controlled hypoPT
Peter Kamenicky
Mon 20
SAT8.6
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Summary and close
Peter Kamenicky
Lars Rejnmark
Sun 19
SAT2.2
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Chronic hypoPT and its impact on symptoms, comorbidities and QoL
Lars Rejnmark
Ferrucio Santini
Sun 19
SAT4.1
Lipodystrophy: a shared journey for patients and care teams
Introduction
Ferrucio Santini
Sun 19
SAT4.4
Lipodystrophy: a shared journey for patients and care teams
The travel journal: patient experiences and collective learnings
Ferrucio Santini
Christian Strasburger
Mon 20
SAT7.1
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Rationale for GH therapy in Adults with GH deficiency
Christian Strasburger
Michael Stumvoll
Sun 19
SAT4.3
Lipodystrophy: a shared journey for patients and care teams
Making the journey: what are our options for treating lipodystrophy?
Michael Stumvoll
Nicholas Tritos
Mon 20
SAT6.3
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Key outcomes: exploring safety and treatment outcomes
Nicholas Tritos
Susan Webb
Sun 19
SAT1.2
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Patient-Reported Challenges: Are We Prepared to Listen? (focus acromegaly)
Susan Webb
Workshop
0
Oral
0
Expert
0
Plenary
0
Catering and Social
0
Nurse
0
Other
0
Symposium
9
Sun 19
13:45
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Ipsen
Forum 2
Chair: Maria Fleseriu (USA)
Sun 19
SAT1.1
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Chairperson’s welcome and introduction
Maria Fleseriu
Oregon, USA
Sun 19
SAT1.2
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Patient-Reported Challenges: Are We Prepared to Listen? (focus acromegaly)
Susan Webb
Sun 19
SAT1.3
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
The Impact of Illness: The Perception Gap Between Us (focus Carcinoid Syndrome)
Simona Glasberg
Sun 19
SAT1.4
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
The real impact of endocrine disease: Understanding the patient perspective
Daphne Adelman
Sun 19
SAT1.5
Living With Debilitating Endocrine Disorders: A Conversation On the Real Patient Experience
Moving Forward Together
Maria Fleseriu
Oregon, USA
Sun 19
13:45
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Merck KGaA
Salle Gratte-Ciel 1+2+3
Chair: George J Kahaly (Germany)
Sun 19
SAT3.1
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Prediabetes: A call for Action
Ian Campbell
Sun 19
SAT3.2
Prevent is better than cure!! Let's talk about prediabetes and induced thyroiditis!
Drug induced thyroiditis: targeting profile patient
Frederic Castinetti
Sun 19
13:45
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Takeda
Forum 1
Chair: Pascal Houillier (France)
Sun 19
SAT2.1
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Welcome and introduction
Pascal Houillier
Sun 19
SAT2.2
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Chronic hypoPT and its impact on symptoms, comorbidities and QoL
Lars Rejnmark
Sun 19
SAT2.3
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Renal complications in the patient with hypoPT
Pascal Houillier
Sun 19
SAT2.4
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Genetic syndromes as a cause of hypoPT: What are the unique challenges?
Maria Luisa Brandi
Florence, Italy
Sun 19
SAT2.5
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Panel discussion and Q&A
Sun 19
SAT2.6
Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Summary and close
Pascal Houillier
Sun 19
17:45
Lipodystrophy: a shared journey for patients and care teams
Aegerion
Salle Gratte-Ciel 1+2+3
Chair: Ferrucio Santini (Italy)
Sun 19
SAT4.1
Lipodystrophy: a shared journey for patients and care teams
Introduction
Ferrucio Santini
Sun 19
SAT4.2
Lipodystrophy: a shared journey for patients and care teams
Planning the journey: suspecting and diagnosing lipodystrophy – the role of leptin deficiency in the disease
Giovani Ceccarini
Sun 19
SAT4.3
Lipodystrophy: a shared journey for patients and care teams
Making the journey: what are our options for treating lipodystrophy?
Michael Stumvoll
Sun 19
SAT4.4
Lipodystrophy: a shared journey for patients and care teams
The travel journal: patient experiences and collective learnings
Ferrucio Santini
Sun 19
SAT4.5
Lipodystrophy: a shared journey for patients and care teams
Discussion
All
Sun 19
17:45
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
HRA Pharma Rare Diseases
Forum 2
Chairs: Antoine Tabarin (France) & Elena Valassi (Spain)
Sun 19
SAT5.1
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
How to preserve bone health?
Iacopo Chiodini
Sun 19
SAT5.2
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Is there a clear path to progress in thrombosis risk reduction?
Richard Feelders
Sun 19
SAT5.3
The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Should neurocognitive functioning be front of mind in management strategies?
Cornelia Andela
Mon 20
13:45
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Pfizer
Forum 2
Chair: Thierry Brue (France)
Mon 20
SAT6.1
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Welcome and Introduction
Thierry Brue
Mon 20
SAT6.2
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
A brief history of ACROSTUDY™
Michael Buchfelder
Erlangen, Germany
Mon 20
SAT6.3
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Key outcomes: exploring safety and treatment outcomes
Nicholas Tritos
Mon 20
SAT6.4
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Impact of treatment on glucose metabolism and patient-reported outcomes
Silvia Grottoli
Mon 20
SAT6.5
ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Summary and Q&A
Thierry Brue
Mon 20
13:45
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Novo Nordisk
Lumiere Auditorium
Chair: Philippe Chanson (France)
Mon 20
SAT7.1
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Rationale for GH therapy in Adults with GH deficiency
Christian Strasburger
Mon 20
SAT7.2
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Updates in the diagnosis and management of Adults GH Deficiency
Beverly Biller
Mon 20
SAT7.3
Updates on the diagnosis and management of Adult Growth Hormone Deficiency (AGHD)
Future developments in the management of AGHD
Gudmundur Johannsson
Mon 20
13:45
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Takeda
Forum 3
Chair: Peter Kamenicky (France)
Mon 20
SAT8.1
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
New perspectives for not adequately controlled hypoPT
Peter Kamenicky
Mon 20
SAT8.2
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Working towards a consensus to define patients with not adequately controlled hypoPT
Peter Kamenicky
Mon 20
SAT8.3
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Treating not adequately controlled hypoPT patients with complications and comorbidities
John Bilezikian
Mon 20
SAT8.4
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Management of not adequately controlled hypoPT patients with impaired biochemical control and complications
Lorenz Hofbauer
Mon 20
SAT8.5
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Panel discussion and Q&A
Mon 20
SAT8.6
New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Summary and close
Peter Kamenicky
Mon 20
18:00
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Advanced Accelerator Applications
Salle Gratte-Ciel 1+2+3
Chairs: Eric Baudin (France) & Woutter de Herder (Netherlands) & Diego Ferone (Italy)
Mon 20
SAT9.1
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Should theragnostics be reserved to a subset of patients?
Eric Baudin
Mon 20
SAT9.2
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
Theragnostics as a new paradigm for all NET patients
Woutter Herder
Mon 20
SAT9.3
Theragnostics in NeuroEndocrine Tumors: from sceptics to believers
What should we do in our practice?
Diego Ferone
No Session Type
4
Sat 18
07:30
Registration
tbc
Sun 19
07:30
Registration
tbc
Mon 20
07:30
Registration
tbc
Tue 21
07:30
Registration
tbc
0 result(s) found.
Please wait...
×
-
×
Abstracts from this event
Abstracts from other events
Session starts at:
Abstract time:
Event:
×